So. Basically a Q&A based on questions from Lisa. All about HAE. 7353 to begin shortly (grrr). Hasn't begun?
I don't know how much more strongly our heroes can stress that a pill that keeps the Kallikrein inhibitor above a threshold level is much preferred over shots.
No mention of Zika. No question asked, and no info volunteered.
Bought 200 shrs in June, 2004 at 8. Sold in 2010 at 10. In and out and around, and feeling like this stock is a roller coaster since. Never can tell what surprises management has in store. I wonder what JMP Q&A will uncover. Hopefully, something good.
It's not just that I'm a greedy shareholder. Aside from institutional ownership, if the general public doesn't see progress, when funds are needed, the company will have to give away too much to get the funds needed. Management surely knows this, so a shrug of the shoulders at another sell side dog and pony show does no good. Share price decay does no good!
Cascadian threw out their management team recently. CASC presented very positive HER2 cancer results in 2015, but failed to disseminate followup info, making investors very jumpy. Stock price plummeted. Does this story sound familiar. Last year the pps for BCRX blossomed with a constant flow of information. This year, a stream of same old, same old. This can't continue! The pps slow creep up over 2 months, finally reaching 4; and then collapse over three days to 2.80. Not good.
Thanks Map. Very interesting presentation. Maddening. Why are the results so secret??? Is this a question of national security? D**n. I don't think we the shareholders are asking too much.
Couldn't listen to the cc because I can't install Limelight in time. Figured it was the same old, same old when the pps didn't continue the climb of the last week. This mgmt. is inept at at least holding the price intact - 10% drop?? What are they doing? Vent over - I'll go back to watching Jack Welch blowing it out his tookis.
Congress should be held accountable for underfunding health research. Always the same, underfund (like they are d##cking around now,) and point the finger when something goes wrong. Term limits, please!
You don't remember last year when the pps rose up to 16 from sub-5 on one piece of good news after another?
This reminds me of OSIP, which was one of my first biotech investments back in 199- whatever. I bought it at 4, went up to 12, fell down to the 1's. That's Wall Street for you -- 'we want it now." But the CEO, Dr Colin Goddard, was dogged in pursuit of the goal, even when they got Tarceva handed back to them by Pfizer. When Tarceva got approved the pps shot up to 84. Slow and steady wins the race. I kind of believe that Mr. Stonehouse and Dr. Sheridan have the same slow and steady mentality, and that Biocryst will succeed.
We desperately need people who understand science process and inquiry in congress. I believe that the last republican to actively support science in congress was Sherwood Boehlert, who led the science and technology committee. He did a sterling job. But that was before partisanship took hold big time.
Retention bonuses should be available only after commercial success! The retention bonus now should be you get to keep your job. Our pps reflects the street opinion of management performance. We seemed to be on an upward path last year, and it then stalled. Too many disappointments. It's really OK in the long run, but shouldn't management contain themselves until the company arrives at the long-term goal? If they're that confident, they will stay put. If not confident, they will take the money and run.
Not happy about his compensation answer. For companies in the development phase, like NVIV and many others, I would consider 1/2 mil total comp value fair. When you start making money with a successful product, then talk about the bigger bucks. Until then, success in the market should be all the incentive an executive needs. Do a good job, keep your job. Mark Perrin apparently did not succeed in his last CEO job, and the company went bankrupt. That's accountability!
I have felt this way for a month. All the talk out there about Zika, including by us at the last cc. And barely any movement in pps (yes we recovered from 1.60.) BCRX management is not making an impression. All those analysts, and they are not hearing the message. Too laid back about this.
BTW, when Jon Stonehouse was at Astra Zeneca, he was responsible for clinical development and commercialization of Prilosec in the US. And now, he's giving heartburn instead of curing it!
"House Republicans, who are demanding offsetting spending cuts."
1 - cut federal funds to your red states - eg, S. Carolina gets almost $8 for every dollar paid in fed. tax
2 - cut your travel perks
3 - cut your cadillac medical plans
4 - cut your noses to spite your ugly do-nothing faces